Kidney cancer "immune and targeted" first-line treatment! Pfizer and Merck Bavencio and Inlyta combination therapy have been approved by NICE IN!

03, 2020 // The National Institute for Health and Clinical Optimization (NICE) has recommended a combination of Merck KGaA and Pfizer's anti-PD-L1 therapy Bavencio (avelumab) and tyrosine kinase inhibitor Inlyta (axinib, attinib) in the NHS.
the scheme will be funded through the Cancer Drugs UK (CDF).
comes after the Bavencio-Inlyta portfolio was approved in August 2019 for early access to the Drug Access Program (EAMS), which has enabled more than 150 patients in the UK to be treated ahead of time.
Despite some progress in recent years, the prognosis of patients with advanced RCC is still very poor, with a five-year survival rate of only about 12%, and more first-line treatment options are urgently needed.
Bavencio-Inlyta is a combination of "immune-targeted" therapy, in which Bavencio is an immunocheckpoint inhibitor for PD-L1, Inlyta is an anti-angiogenic VEGF-targeted TKI, and the complementary mechanism of two drugs targets 2 key pathways for tumor growth.
in the United States and the European Union, the Bavencio-Inlyta portfolio was approved in May and October 2019 for first-line treatment of patients with advanced RCC.
note, in April and September of the same year, the combination of Mercado anti-PD-1 therapy Keytruda and Inlyta was approved in the United States and the European Union, respectively, for first-line treatment of patients with advanced RCC.
data from the Phase III JAVENLIN Renal 101 study showed that the Bavencio-Inlyta combination significantly reduced the risk of disease progression or death by 31% and the overall mitigation rate (ORR) nearly doubled (52.5% vs 27.3%) in all prognosis risk groups (regardless of PD-L1 status).
currently, the study is under way to determine the overall lifetime benefits. Professor Amit Bahl, medical oncologist who specializes in renal cell carcinoma at the
, said: "This positive recommendation from NICE provides an effective and well-tolerated treatment for patients with advanced kidney cancer, and the results from the random phase III trial confirm the benefits of Bavencio-Inlyta combination therapy in terms of progression-free survival and objective remission rates.
" Inlyta, developed by Pfizer, is an oral therapy designed to inhibit tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, which may promote tumor growth, angiogenesis and cancer progression (tumor diffusion).
in the United States and the European Union, Inlyta is approved for second-line treatment of advanced RCC.
Bavencio was developed by Merck and is part of PD-(L) 1 tumor immunotherapy, a high-profile type of tumor immunotherapy designed to use the body's own immune system to fight cancer, by blocking the PD-1/PD-L1 signaling pathway to kill cancer cells, has the potential to treat a variety of types of tumors.
november 2014, Pfizer signed a $2.85 billion deal with Merck to enter PD-(L1.
so far, Bavencio's approved indications include: (1) treatment of patients with local late or metastatic urinary tract skin ;( cancer (UC) for the treatment of patients with advanced or metastatic urethral skin cancer (UC) during or after platinum chemotherapy or after chemotherapy;
(4) treat patients with advanced renal cell carcinoma (RCC) with a combination of Bavencio and Inlyta therapy.
(5) for maintenance therapy in patients with locallate or metastatic UC who did not progress with first-line platinum chemotherapy, which was approved at the end of June 2020.
note, Bavencio is the first FDA-approved immunotherapy in the U.S. to have proven significant total survival (OS) benefits in first-line maintenance therapy UC III clinical trials.
data from the Phase III JAVELIN Bladder 100 Study show editing the median OS by 50% (21.4 months vs 14.3 months) compared to standard care.
() Original source: NICE backs Bavencio combo for kidney cancer.